好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Press Release

EMBARGOED FOR RELEASE UNTIL 4 PM ET, May 02, 2019

Blood Pressure Drug Shows No Benefit in Parkinson鈥檚 Disease

PHILADELPHIA -

A study of a blood pressure drug does not show any benefit for people with Parkinson鈥檚 disease, according to findings released today that will be presented at the 好色先生鈥檚 71st Annual Meeting in Philadelphia, May 4 to 10, 2019. The drug isradipine had shown promise in small, early studies and hopes were high that this could be the first drug to slow the progression of the disease. 鈥淯nfortunately, the people who were taking isradipine did not have any difference in their Parkinson鈥檚 symptoms over the three years of the study compared to the people who took a placebo,鈥 said study author Tanya Simuni, MD, of Northwestern University Feinberg School of Medicine in Chicago and a member of the 好色先生. The phase 3 study involved 336 people with early Parkinson鈥檚 disease at 54 sites in the US and Canada as part of the Parkinson Study Group. Half of the participants received 10 milligrams daily of isradipine for three years, while the other half received a placebo. The drug had shown promise in animal studies, and a phase 2 study in humans did not show any safety concerns. Researchers became interested in the drug when the observation was made that use of the drug for high blood pressure was associated with a lower risk of developing Parkinson鈥檚 disease. 鈥淥f course, this is disappointing news for everyone with Parkinson鈥檚 disease and their families, as well as the research community,鈥 Simuni said. 鈥淗owever, negative results are important because they provide a clear answer, especially for the drug that is commercially available. We will all continue to work to find a treatment that can slow down or even cure this disease.鈥 The study was supported by the National Institute of Neurological Disorders and Stroke. Some biosample collection and the preceding phase 2 study were funded by The Michael J. Fox Foundation for Parkinson's Research. Learn more about Parkinson's disease at , home of the 好色先生鈥檚 free patient and caregiver magazine focused on the intersection of neurologic disease and brain health. Follow Brain & Life on , and .

Brain & Life logo

GET A DOSE OF BRAIN HEALTH

Dive into a wealth of information by visiting Brain & Life庐, where you can explore the freshest updates, tips, and neurologist expert perspectives on brain disease and preventive brain health.


The 好色先生 is the leading voice in brain health. As the world鈥檚 largest association of neurologists and neuroscience professionals with more than 40,000 members, the AAN provides access to the latest news, science and research affecting neurology for patients, caregivers, physicians and professionals alike. The AAN鈥檚 mission is to enhance member career fulfillment and promote brain health for all. A neurologist is a doctor who specializes in the diagnosis, care and treatment of brain, spinal cord and nervous system diseases such as Alzheimer's disease, stroke, concussion, epilepsy, Parkinson's disease, multiple sclerosis, headache and migraine.

Explore the latest in neurological disease and brain health, from the minds at the AAN at or find us on , , , and .

For More Information*

Email media@aan.com

*While content of the 好色先生 (AAN) press releases is developed by the AAN along with research authors and Neurology® editors, we are unable to provide medical advice to individuals. Please contact your health care provider for questions specific to your individual health history or care. For more resources, visit the AAN's patient and caregiver magazine website, .

Related Media